GRAIL's Galleri Test Volume Surges 35% as FDA Review Nears — GRAIL, Inc.

Event summary

Galleri test volume increased 35% year-over-year to over 61,000 tests in Q2 2026
Total revenue grew 26% year-over-year to $44.7 million in Q2 2026
Completed $110 million equity financing with Samsung C&T and Samsung Electronics
FDA advisory committee expected in fall 2026 for Galleri's Premarket Approval application

The big picture

GRAIL's strong Q2 2026 results highlight the growing demand for early cancer detection solutions. The company's strategic partnerships and upcoming FDA review position it at the forefront of the multi-cancer early detection (MCED) market, which is poised to disrupt traditional cancer screening methods. With a robust cash position and expanding commercial reach, GRAIL is well-positioned to capitalize on the shift towards proactive healthcare.

What we're watching

Regulatory Approval: The pace at which the FDA advisory committee reviews Galleri's PMA application will determine commercialization timelines.
Market Expansion: GRAIL's collaboration with Samsung for Asian market expansion could significantly increase revenue streams if regulatory approvals are secured.
Operational Efficiency: Whether GRAIL can sustain its 34% adjusted gross profit growth amid increasing sales and marketing expenses.